TS
NGM

Thomas Steyer’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Thomas Steyer’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-375,000
Closed -$10.9M – 319
2021
Q1 		$10.9M Buy
+375,000
New +$10.5M 0.05% 133

Other funds holding NGM

CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Thomas Steyer's NGM Position: Q2 2021 in Review

Thomas Steyer sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2021, closing a stake of 375,000 shares — an estimated $10.9M sold.

Thomas Steyer first reported a position in NGM in Q1 2021 and held it in 1 quarter. The position peaked at $10.9M in Q1 2021. 107 funds tracked by Wall St. Rank hold NGM as of Q2 2021.

  • Thomas Steyer reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Thomas Steyer sold 375,000 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $10.9M.
  • Thomas Steyer first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Thomas Steyer's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $10.9M in Q1 2021.
  • 107 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Farallon Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.